Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Pivotal trial to evaluate ozureprubart (JYB1904) in Patients With Chronic Spontaneous Urticaria

Next Previous
Trial Profile

Phase III Pivotal trial to evaluate ozureprubart (JYB1904) in Patients With Chronic Spontaneous Urticaria

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ozureprubart (Primary)
  • Indications Chronic urticaria
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 17 Nov 2025 New trial record
  • 20 Oct 2025 According to RAPT Therapeutics media release, based on the positive results from phase II trial company is moving to a pivotal Phase 3 trial in CSU and plans to discuss next steps with the FDA and other regulatory authorities.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top